E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Chronic Obstructive Pulmonary Disease (COPD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of GW685698 /GW642444 administered once-daily for 4 weeks in subjects with COPD. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the systemic pharmacokinetic (PK) profile of the individual components and the pharmacodynamic (PD) profile of the combination when administered once-daily for 4 weeks in subjects with COPD. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects eligible for enrolment in the study must meet all of the following criteria: 1. Informed consent: Subjects must give their signed written informed consent to participate. 2. Gender: Male subjects or female subjects of non-child bearing potential (e.g. post-menopausal or surgical sterile) 40 - 80 years of age at screening (Visit 1). • Post-menopausal females are defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However if indicated this can be confirmed by estradiol and FSH levels consistent with menopause (according to laboratory ranges) at screening (Visit 1). • Surgically sterile females are defined as those with a documented (medical report verification) hysterectomy and/or bilateral oophorectomy or Tubal Ligation. • Furthermore, male subjects in this study must use double-barrier (condom/spermicide) birth control methods or abstain from sexual intercourse with female partners who are pregnant, lactating, or able to bear children in addition to any birth control methods the female partner is using, from the first dose of the study medication until 90 days after the last dose of the study medication. 3. COPD diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004] : COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences. 4. Tobacco use: subjects with a current or previous history of =/>10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. • Number of pack years = (number of cigarette per day/20)) x number of years smoked 5. Severity of Disease: subjects who conform to the current severity classification for Stage II/III disease in terms of post-bronchodilator spirometry at Screening Visit 1: • Subject with a measured post-salbutamol FEV1/FVC ratio of =/< 0.70 •Subjects with a measured post-salbutamol FEV1 =/> 40 % and =/< 80 % of predicted normal values calculated using NHANES III reference equations.
|
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following criteria must not be enrolled in the study: 1. Pregnancy: Women who are pregnant or lactating 2. Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if COPD is the current diagnosis) 3. Alpha 1- antitrypsin deficiency: Subjects with Alpha-1 antitrypsin deficiency as the underlying cause of COPD 4. Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases 5. Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening 6. Chest X-ray (or CT scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening if a chest X-ray or CT scan is not available within 6 months prior to Screening 7. Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the occurrence of any of the following in the 2 months prior to Screening: • Acute worsening of COPD that requires medication (e.g. oral corticosteroid, antibiotics) prescribed by a physician, or • Acute worsening of COPD for which the subject is hospitalized. 8. Lower respiratory tract infection: Subjects with lower respiratory tract infection that required the use of antibiotics within 6 weeks prior to Visit 1 9. 12-lead ECG (Electrocardiogram): An abnormal and clinically significant 12-lead ECG result. For this study, an abnormal ECG is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: • Clinically significant conduction abnormalities (e.g. left bundle branch block, Wolff-Parkinson-White syndrome) • Clinically significant arrhythmias (e.g. atrial fibrillation, ventricular tachycardia) The investigator will determine the clinical significance of any ECG abnormalities and determine if a subject is precluded from entering the study. However, the following predetermined ECG abnormalities are considered clinically significant and will result in exclusion of a subject: Please view protocol for further information. 10. Other Diseases/abnormalities: Please view protocol for further information. 11. Hepatitis: Subjects with a positive Hepatitis B surface antigen or positive Hepatitis C antibody pre-study or at Screening 12. Hypertension: Uncontrolled hypertension, defined as a supine blood pressure equal to or higher than 150/95 mmHg at Screening in subjects NOT receiving medication for hypertension; or • Uncontrolled hypertension, defined as a supine blood pressure equal to or higher than 140/95 mmHg at Screening in subjects receiving medication for hypertension (refer to ‘prohibited medications’) 13. Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Please view protocol for further information. 14. Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). Please view protocol for further information. 15. Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years 16. Medication prior to spirometry: Subjects who are medically unable to withhold their rescue medication for the 6-hour period required prior to spirometry testing at each study visit. 17. Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e. =/< 12 hours per day) is not exclusionary. 18. Pulmonary rehabilitation: Subjects, who have participated in the acute phase of a Pulmonary Rehabilitation Programme within 4 weeks prior to Screening, please view protocol for further information. 19. Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures 20. Questionable validity of Consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study 21. Prior use of study medication/other investigational drugs: Subjects who have received the GW642444 in previous studies. Please view protocol for further information. 22. Sleep apnea: Subjects with clinically significant sleep apnea that is uncontrolled. 23. History of any adverse reactions: including immediate or delayed hypersensitivity to any beta-agonist, ICS or sympathomimetic drugs)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Change from baseline in weighted mean heart rate 0-4 hrs post-dose at the end of the 28 days treatment period • Incidence of AEs throughout the study.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |